Nature Reviews Urology最新文献_第8页

The interplay between male fertility, mental health and sexual function 男性生育能力、心理健康和性功能之间的相互作用。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-27 DOI: 10.1038/s41585-024-00936-1

Vincent J. Straub, Melinda C. Mills

引用次数: 0

Immune effects of α and β radionuclides in metastatic prostate cancer α和β放射性核素对转移性前列腺癌的免疫效应

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-27 DOI: 10.1038/s41585-024-00924-5

Sapna Lunj, Tim Andrew Davies Smith, Kimberley Jayne Reeves, Fred Currell, Jamie Honeychurch, Peter Hoskin, Ananya Choudhury

{"title":"Immune effects of α and β radionuclides in metastatic prostate cancer","authors":"Sapna Lunj, Tim Andrew Davies Smith, Kimberley Jayne Reeves, Fred Currell, Jamie Honeychurch, Peter Hoskin, Ananya Choudhury","doi":"10.1038/s41585-024-00924-5","DOIUrl":"10.1038/s41585-024-00924-5","url":null,"abstract":"External beam radiotherapy is used for radical treatment of organ-confined prostate cancer and to treat lesions in metastatic disease whereas molecular radiotherapy with labelled prostate-specific membrane antigen ligands and radium-223 (223Ra) is indicated for metastatic prostate cancer and has demonstrated substantial improvements in symptom control and overall survival compared with standard-of-care treatment. Prostate cancer is considered an immunologically cold tumour, so limited studies investigating the treatment-induced effects on the immune response have been completed. However, emerging data support the idea that radiotherapy induces an immune response in prostate cancer, but whether the response is an antitumour or pro-tumour response is dependent on the radiotherapy regime and is also cell-line dependent. In vitro data demonstrate that single-dose radiotherapy regimes induce a greater immune-suppressive profile than fractionated regimes; less is known about the immune response induced by molecular radiotherapy agents, but evidence suggests that these agents might induce an immune-suppressive systemic immune response, indicated by increased expression of inhibitory checkpoint molecules such as programmed cell death 1 ligand 1 and 2, and that these changes could be associated with clinical response. Different radiotherapy modalities can induce distinct immune profiles, which can either activate or suppress immune-mediated tumour killing and the current preclinical models used for prostate cancer research are not yet optimal for studying the complexity of the radiotherapy-induced immune response. This Review focusses on what is known about the interactions between conventional radiotherapy and the immune system. The authors discuss how this knowledge can be applied to investigate gaps regarding the immune interactions of molecular radiotherapies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"21 11","pages":"651-661"},"PeriodicalIF":12.1,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Field effect and forerunner genes drive bladder cancer initiation 场效应和先驱基因驱动膀胱癌的发生

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-12 DOI: 10.1038/s41585-024-00929-0

Maria Chiara Masone

引用次数: 0

AI for drug discovery 人工智能促进药物研发

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00931-6

Louise Lloyd

引用次数: 0

Utility of PSA screening in transgender women receiving oestrogens 接受雌激素治疗的变性女性接受 PSA 筛查的效用

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00930-7

Maria Chiara Masone

引用次数: 0

Urology’s carbon footprint 泌尿外科的碳足迹

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00934-3

Louise Lloyd

引用次数: 0

Immunotherapy for penile cancer 阴茎癌免疫疗法

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00932-5

Louise Lloyd

引用次数: 0

Single-cell analysis of advanced prostate cancer 晚期前列腺癌的单细胞分析

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00933-4

Louise Lloyd

引用次数: 0

Accurate information provided by artificial intelligence 人工智能提供的准确信息。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-08 DOI: 10.1038/s41585-024-00928-1

Louise Lloyd

引用次数: 0

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer 高危局部前列腺癌的新辅助卢塞恩 PSMA、TIME 和免疫反应。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-07 DOI: 10.1038/s41585-024-00913-8

Renu S. Eapen, Scott G. Williams, Sean Macdonald, Simon P. Keam, Nathan Lawrentschuk, Lewis Au, Michael S. Hofman, Declan G. Murphy, Paul J. Neeson

{"title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","authors":"Renu S. Eapen, Scott G. Williams, Sean Macdonald, Simon P. Keam, Nathan Lawrentschuk, Lewis Au, Michael S. Hofman, Declan G. Murphy, Paul J. Neeson","doi":"10.1038/s41585-024-00913-8","DOIUrl":"10.1038/s41585-024-00913-8","url":null,"abstract":"High-risk localized prostate cancer remains a lethal disease with high rates of recurrence, metastases and death, despite attempts at curative local treatment including surgery. Disease recurrence is thought to be a result of failure of local control and occult micrometastases. Neoadjuvant strategies before surgery have been effective in many cancers, but, to date, none has worked in this setting for prostate cancer. Prostate-specific membrane antigen (PSMA)-based theranostics is an exciting and rapidly evolving field in prostate cancer. The novel intravenous radionuclide therapy, [177Lu]Lu-PSMA-617 (lutetium PSMA) has been shown to be effective in treating men with metastatic castration-resistant prostate cancer, targeting cells expressing PSMA throughout the body. When given in a neoadjuvant setting, lutetium PSMA might also improve long-term oncological outcomes in men with high-risk localized disease. A component of radiotherapy is potentially an immunogenic form of cancer cell death. Lutetium PSMA could cause cancer cell death, resulting in release of tumour antigens and induction of a tumour-specific systemic immune response. This targeted radioligand treatment has the potential to treat local and systemic tumour sites by directly targeting cells that express PSMA, but might also act indirectly via this systemic immune response. In selected patients, lutetium PSMA could potentially be combined with systemic immunotherapies to augment the antitumour T cell response, and this might produce long-lasting immunity in prostate cancer. Lutetium PSMA is approved for the treatment of advanced prostate cancer and is being studied in a neoadjuvant setting. The influence of lutetium PSMA on the tumour immune microenvironment is unknown. In selected patients, lutetium PSMA could be used as a stand-alone treatment or in combination with immunotherapy to produce long-lasting antitumour immunity.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"21 11","pages":"676-686"},"PeriodicalIF":12.1,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0